Fibrotic diseases are known to affect several vital organs in the body and are a major cause of mortality and morbidity. There has been a little success in treatment of these diseases so far. ILB®, the Low Molecular 重量 Dextran Sulfate (LMW-DS) has shown promising results in a pre-临床 trial. It has been found to resolve inflammation and activate matrix remodelling in rodent and human disease models. Apparently, ILB® seems to have the potential to treat fibrotic diseases. Of particular interest is the possibility of anti-fibrotic treatment for glaucoma. But before getting approved, it needs to undergo further large scale 临床 试验。
当由于感染、自身免疫、毒素、辐射、机械损伤等因素引发炎症持续较长时间(慢性炎症)时,组织重塑和修复过程同时发生。 修复过程有两个阶段 - 再生(相同类型的新细胞替换受损细胞)和 纤维化 (结缔组织取代正常细胞)。 当不受控制时,修复过程会导致细胞外基质 (ECM) 沉积,最终导致正常组织被永久性疤痕组织取代。
由于慢性和未解决的异常纤维化 炎症 它很常见,并且是影响肺、肝、心脏、胰腺、眼睛、脑、肠、皮肤等重要器官的大量疾病背后的关键病理学。这些疾病是全世界死亡率和发病率的主要原因。 据估计,所有死亡中约有 45% 归因于纤维化。 纤维化疾病的治疗通常不成功,因为需要一种合适的治疗剂来解决炎症、阻止异常纤维化并激活正常细胞的再生。 组织 从而恢复正常的组织稳态而不会产生副作用。 任何这样的治疗剂都将具有重大的社会和经济意义。
In earlier study, ILB® has already been demonstrated to be safe in humans. In this study, researchers investigated low molecular 重量 dextran sulfates (LMW-DS) in rodent and human disease models. It was found that ILB®, the Low Molecular 重量 Dextran Sulfate (LMW-DS) –
- 调节炎症和 伤口愈合 培养的人体细胞中的反应,
- 调节培养的人类细胞中炎症和纤维化基因的表达,以及
- 降低培养的人小梁网细胞中的纤连蛋白水平,并解决青光眼啮齿动物模型中的炎症疤痕。
Thus, the results of this pre-临床 trial suggests that LMW-DS may resolve inflammatory scarring and promote functional tissue regeneration. This proof of concept makes ILB® a potential candidate for treatment of several fibrotic diseases including glaucoma.
***
来源:
- Hill, LJ, Botfield, HF, Begum, G. 等。 2021. ILB® 解决炎症性疤痕并促进功能性组织修复。 发布时间:07 年 2021 月 6 日。npj 再生医学第 3 卷,文章编号:XNUMX。DOI: https://doi.org/10.1038/s41536-020-00110-2
- Wynn TA 2006。纤维化的细胞和分子机制。 《病理学杂志》第 214 卷,第 2 期。首次出版时间:27 年 2007 月 XNUMX 日。DOI: https://doi.org/10.1002/path.2277
***